Non-invasive monitoring cancer using integrated microfluidic profiling of circulating microvesicles
US10350599B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Nov 21, 2016 |
| Grant date | Jul 16, 2019 |
| Priority date | — |
| Expiry date | Nov 21, 2036 |
Classification
- Technology area (CPC B)Performing Operations; Transporting
- CPC primaryB01L2400/0487
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
A microfluidic exosome profiling platform integrating exosome isolation and targeted proteomic analysis is disclosed. This platform is capable of quantitative exosomal biomarker profiling directly from plasma samples with markedly enhanced sensitivity and specificity. Identification of distinct subpopulation of patient-derived exosomes is demonstrated by probing surface proteins and multiparameter analyzes of intravesicular biomarkers in the selected subpopulation. The expression of IGF-1R and its phosphorylation level in non-small cell lung cancer (NSCLC) patient plasma is assessed as a non-invasive alternative to the conventional biopsy and immunohistochemistry. Detection of ovarian cancer also is assessed. The microfluidic chip, which may be fabricated of a glass substrate and a layer of poly(dimethylsiloxane), includes a serpentine microchannel to mix a fluid and a microchamber for the collection and detection of exosomes.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.